Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Hutchmed (China) Ltd. HCM

12 fiscal years on record · USD · FY2025 reported · SEC filings only
$548.5M
▼ 13.0% YoY
$456.9M
▲ 1111.0% YoY
$-78.8M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Through its Oncology/Immunology operations, its team of approximately 870 scientists and staff has created, developed and in-licensed a portfolio of clinical-stage drug candidates. Through its Other Ventures operations, it manufactures, markets and distributes prescription drugs in China. Its Distribution Business is a consolidated joint venture in which it holds 51% interests, with the remaining 49% held by Sinopharm, and, as of December 31, 2025, the Distribution Business had a dedicated team of around 40 commercial staff marketing about 1,100 third-party prescription drug and other products directly to about 830 public and private hospitals in the Shanghai region and through a network of approximately 90 distributors covering all other provinces in China. The company started in China in 2000 and has since expanded its oncology and immunology drug development operations globally.

Written from the business description in HUTCHMED (China) Ltd's annual report to the U.S. Securities and Exchange Commission, filed 5 March 2026. Every sentence was checked against that document before publication.

Growth

USD 548.5M
Revenue, FY2025 · full 12-year series below
Revenue $M Net income $M
FY2025 · Revenue 548.5 · Net income 456.9
300M600M-150M-300M
20142017202020232025
Compound annual growth
+8.8%
+19.2%
+11.9%
+49.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +19.2% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

83 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating -7.1% · Net 83.4%
50%-50%
201420192025
ROE
FY2025 · ROE 45.7%
20%40%-20%-40%
201420192025
Three returns, three denominators.

Each USD of equity produced 46 cents of profit this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -78.8
100M200M-150M-300M
201420192025
Net buybacks $M Dividends $M
FY2024 · Dividends · · Net buybacks 35.3
-250.0M-500.0M
2015201620172018201920202021202220232024

Total assetsUSD 1.8B
EquityUSD 1.2B
CashUSD 71.3M
Gross debtUSD 93.2M
Net debtUSD 21.8M
DepositsUSD 1.7M

Net debt stands at 2% of equity.

The 12-year record

12 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
HCM, 12-year financial record
Metric 202520242023202220212020201920182017201620152014
Revenue $B0.50.60.80.40.40.20.20.20.20.20.20.1
Operating income $B−0.0−0.00.0−0.4−0.3−0.2−0.1−0.1−0.1−0.0−0.0−0.0
EBITDA $B−0.0−0.00.0−0.4−0.3−0.2−0.1−0.1−0.1−0.0−0.0−0.0
Income tax $B0.10.00.0−0.00.00.00.00.00.00.00.00.0
Net income $B0.50.00.1−0.4−0.2−0.1−0.1−0.1−0.00.00.0−0.0
Free cash flow $B−0.1−0.00.2−0.3−0.2−0.1−0.1−0.0−0.0−0.0−0.00.0
EPS, diluted $0.520.040.12−0.43−0.25−0.18−0.16−0.11−0.040.20−0.64−0.62
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————
ROE %45.75.115.0−45.2−26.5−32.6−31.3−17.6−8.38.79.6◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 46 reconciliationsAUDITED

Reconciled in 12 of the 12 fiscal years we could check. 16 checks were skipped: the balance sheet is not tagged before 2015. Seven checks were skipped: EPS is not tagged before 2014. Seven checks were skipped: revenue is not tagged before 2014.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code E9
Fiscal year endsnot stated in the filings
Data on record since2014

Share this section

Download image